AIGISRx Antibacterial Envelope Study Results

• by admin
• 2013-05-15 09:05:05
• General Posting
• 1403 views
• 0 comments

Dr. Charles Henrikson, the Chief of Electrophysiology at the Oregon Health Sciences University, presented new prospective data on 1,000 patients showing 95% fewer major CIED infections in patients undergoing CIED replacement procedures using the AIGISRx Antibacterial Envelope compared to similar high-risk cohorts. These results were presented during the Late Breaking Clinical Trials session at Heart Rhythm 2013.

CITADEL / CENTURION is a prospective, multicenter clinical study to evaluate the major device infection and mechanical complication rates in the 12 months after implantation, in patients at high risk for CIED infection who have their CIED implanted with an AIGISRx Antibacterial Envelope. Study patients were enrolled at 55 US centers, and were at high-risk for infection because they were undergoing a CIED replacement procedure with an implantable cardioverter-defibrillator (ICD), (CITADEL), or a cardiac resynchronization therapy (CRT) device (CENTURION).

For more details, visit www.tyrx.com